Mounjaro®
Starting from £179.99/mo
Start journey Learn moreA faster heartbeat at rest while taking Wegovy (semaglutide) is a recognised side effect documented in clinical trial data — not a sign the medicine has stopped working or that something serious has necessarily gone wrong. Most people who notice it describe a mild, transient increase in resting pulse, typically most noticeable in the weeks after starting or after a dose increase. That said, a heart rate that feels uncomfortable, persistent, or unusually fast deserves proper clinical attention. Wegovy is a prescription-only medicine; any change in symptoms you find concerning should be discussed with your prescribing team.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Many people who notice their heart beating faster at rest assume it signals a serious cardiac problem. That reaction is understandable, but for most people on Wegovy it reflects a pharmacological effect rather than injury. GLP-1 receptors are present in heart tissue, and semaglutide's activation of those receptors has a small, well-characterised effect on heart rate. The STEP 1 trial (a 68-week, placebo-controlled study published in the New England Journal of Medicine) recorded a modest average increase in resting heart rate among participants taking 2.4mg semaglutide, consistent with findings across the Wegovy clinical programme. Researchers noted it was generally mild and did not translate into adverse cardiovascular outcomes for the participants studied. Separately, the large SELECT trial showed Wegovy reduced major cardiovascular events in people with established heart disease and obesity, which underlines why a mildly elevated pulse at rest is not the same thing as cardiac harm. This doesn't mean every racing heart on semaglutide should be ignored. It means the starting assumption shouldn't be alarm. Understanding what's likely, and what warrants urgent attention, is the more useful frame.
You can read more about how Wegovy interacts with heart health more broadly, including the cardiovascular evidence base.
Patients describe the sensation differently: some notice it as a subtle awareness of their heartbeat that wasn't there before; others feel a genuine pounding, particularly when lying down in the evening. The underlying cause is GLP-1 receptor activation in cardiac and nervous system tissue, which can nudge sympathetic tone upward, the same system responsible for the "fight or flight" response. The effect tends to surface in the first few weeks of a new dose. Dehydration makes it more noticeable; nausea and vomiting (both common early side effects) reduce fluid intake, and a lower fluid volume means the heart has to work harder to maintain blood pressure. So the racing sensation is often a convergence of the direct pharmacological effect and a secondary hydration issue rather than one cause acting alone. Caffeine, poor sleep and anxiety about the symptom itself can compound it further. For most people it settles as the body adapts. If yours hasn't eased after two to three weeks at a steady dose, that's worth mentioning to your prescriber rather than waiting for the next scheduled check-in. More detail on what semaglutide does to resting heart rate over time is covered in a dedicated page if you want the deeper clinical picture.
Most cases are mild and self-limiting. Some are not. The NHS medicines information for semaglutide lists a fast or irregular heartbeat as something to tell a doctor about, especially if it does not resolve. Seek medical help without delay if your resting pulse feels very fast (above 100 beats per minute consistently), irregular or accompanied by: chest tightness or pain; shortness of breath at rest; lightheadedness or near-fainting; or palpitations that feel more like a flutter or a skipped beat rather than a steady but elevated rate. Those patterns can point to arrhythmia, dehydration-driven haemodynamic stress, or another unrelated cardiac cause that needs investigation in its own right. Severe, persistent stomach pain that reaches through to the back (separate from any heart symptom) should also prompt urgent assessment; that combination is a warning sign for pancreatitis, which the MHRA highlighted in a Drug Safety Update for GLP-1 medicines in January 2026. Report unexpected or serious reactions via the MHRA Yellow Card scheme. If you are in any doubt, err on the side of calling 111 or your GP rather than waiting.
For context on the broader range of cardiovascular effects reported with Wegovy, our page on Wegovy and heart rate changes covers the clinical evidence in more detail, and our Wegovy fast heart rate page addresses situations where the pulse is high rather than merely elevated.
First, check your hydration. Aim for consistent fluid intake across the day; the nausea that often accompanies semaglutide makes many people drink less without realising it, and that alone can tip a mild heart-rate rise into a more unsettling one. Second, note the pattern: when in your weekly cycle does it happen? Many people find it peaks in the day or two after their injection and eases by mid-week, a clue that timing and peak drug concentration play a role. Third, tell your prescribing team. If you're being reviewed for a private Wegovy prescription, you have access to aftercare support to raise exactly this kind of question. A prescriber can assess whether the pattern is expected, whether your dose schedule needs reviewing, or whether a separate investigation is appropriate. At nume, aftercare is available seven days a week, questions like this are exactly what it exists for. If you started Wegovy recently and are still in the early adjustment period, our Wegovy overview page covers what the first few months of treatment typically look like. Should any concern make you want to pause and get a clinical view before continuing, checking your eligibility with our prescribers is the right first step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.